From Lab to Dance Floor
Imagine a drug that makes you feel like the best version of yourself, a substance that melts away stress and fills you with a deep sense of connection and love for the world and the people around you. For many, that’s the experience of MDMA, often called ecstasy. But this drug is making headlines for a far more serious reason: its potential as a powerful medicine.
Recent scientific discoveries suggest that MDMA may be able to heal anxiety and even cure severe post-traumatic stress disorder (PTSD). Australia has become the first country in the world to legalize the prescription of MDMA for certain complex mental health conditions, signaling a major shift in how we view psychedelic substances.
A Medicinal Past and a Misunderstood Present
The story of MDMA isn’t what you might expect. It was first created in 1912 by the pharmaceutical company
Merck, which was trying to develop a medicine to stop bleeding. However, it wasn’t given to people until the 1960s and 70s, when researchers like Alexander Shulgin, the “godfather of ecstasy,” began exploring its therapeutic potential.
Dr. George Greer, a psychiatrist in San Francisco, recalls the drug’s early days. After experiencing its profound ability to facilitate openness and communication, he was convinced it could be a valuable tool in therapy. So, in the early 1980s, he decided to test it with his own patients. Since MDMA was in a legal “gray area,” he couldn’t buy it, so he made it himself with the help of a chemist. The result was a “pure white powder” that helped his patients open up and make significant progress.
Greer published a study on his findings, following 29 people who, after a session with MDMA, reported greater insight into their problems and felt more relaxed and calm long after the drug’s effects had worn off. He believed he had discovered a groundbreaking new medicine. But in 1983, when MDMA started to appear at New York cocktail parties, Greer knew the end was near. He was right. In 1985, the Drug Enforcement Administration (DEA) made it illegal, stating it had “no legitimate medical use” and posed a “significant risk to public health”.
How MDMA Works on the Brain
Why does MDMA create such a powerful feeling of closeness and connection? It’s similar to amphetamines—its full name is MethyleneDioxy MethAmphetamine—but it has a unique effect on the brain. A key part of the process involves
serotonin, a neurotransmitter that affects mood. MDMA latches onto the protein that normally removes serotonin from the brain, allowing it to linger and creating a heightened sense of well-being.
However, the full story is more complex, according to Dr. Harriet de Wit, a professor at the University of Chicago. MDMA also affects other neurotransmitters, like dopamine and norepinephrine, as well as the bonding hormone
oxytocin.
Dr. de Wit’s research has also revealed a remarkable “superpower” of MDMA: it can make people less sensitive to negative emotions and judgmental expressions. In one study, people on MDMA showed less brain activity when viewing angry faces. This happens because the drug appears to dampen activity in the
amygdala, the part of the brain linked to fear.
A Profound, Unexpected Transformation
In one of her studies, Dr. de Wit gave MDMA to a participant and then, after he left, received a cryptic note from him saying, “Now I know what I have to do. Google my name”. When her team looked him up, they discovered he was the leader of a white supremacist group. Fearing the drug had made him more violent, they immediately asked him what he meant.
His answer was a shock: he had realized that the most important thing in life is
love. A single dose of MDMA helped him re-evaluate his values and conclude that his racist beliefs were insignificant compared to human connection. While this was a single, anecdotal case, it powerfully illustrates the drug’s potential for profound, transformative change.
The Truth About the “Comedown” and Brain Damage
Many recreational users of MDMA report feeling a crash or depression in the days after, a phenomenon known as the “Tuesday Blues” or even “Suicide Tuesday”. While some studies support this idea, others—including Dr. de Wit’s research—do not. This suggests that the comedown might not be a direct result of the drug itself, but rather a combination of factors, such as dehydration, lack of sleep, or other substances consumed during a party.
A common fear is that MDMA “fries your brain”. This belief was fueled by a retracted study on monkeys where the researchers accidentally gave the animals methamphetamine instead of MDMA. While a single dose is unlikely to cause lasting harm, heavy and continuous use of MDMA is almost certainly damaging to the brain. A review of studies on over 1,000 heavy users found that they had more difficulty with memory and switching between tasks. However, for occasional use, the evidence of lasting brain damage is weak.
The Real Dangers of MDMA
So, is MDMA completely safe? The biggest risk isn’t the drug itself, but what’s in it. On average, 43 deaths per year in England and Wales are linked to MDMA, out of an estimated one million users. But these deaths are often not the result of pure MDMA. The MDMA sold on the street is rarely made by professional chemists, and it’s frequently contaminated with other, more dangerous substances.
For example, a study from 2015 found that more than 40% of people who claimed they had never used “bath salts”—a dangerous group of synthetic drugs—had traces of them in their hair. A more recent concern is the presence of
fentanyl, a deadly opioid, which has been found in MDMA samples. Studies in the UK, Spain, and Australia suggest that roughly one in five street samples of MDMA is adulterated.
Conclusion
There’s a common misconception that a drug that feels so good must have terrible consequences. But as one researcher put it, “Chemicals don’t work like that—they don’t decide to punish you for having too much fun”. From what we know now, MDMA is a relatively safe drug when used in controlled settings and, for some, it has the potential to be a truly powerful medicine for healing the mind.
Reference
- https://www.dea.gov/factsheets/ecstasy-or-mdma-also-known-molly
- Betzler, F., Viohl, L., & Romanczuk‐Seiferth, N. (2017). Decision‐making in chronic ecstasy users: a systematic review. European journal of neuroscience, 45(1), 34-44. https://onlinelibrary.wiley.com/doi/10.1111/ejn.13480
- Roberts, C. A., Quednow, B. B., Montgomery, C., & Parrott, A. C. (2018). MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent ‘Ecstasy’users. Neuroscience & Biobehavioral Reviews, 84, 470-482.https://www.sciencedirect.com/science/article/pii/S014976341630851X#bib0290
- https://www.geoverdose.it/
- Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., … & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature medicine, 27(6), 1025-1033.https://psychiatryonline.org/doi/full/10.1176/appi.focus.23021011
- Wagner, A. C. (2021). Couple therapy with MDMA—proposed pathways of action. Frontiers in Psychology, 12, 733456.https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2021.733456/full
- Therapeutic Goods Administration. (2023). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Australian Goverment, Department of Health and Aged Care.https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
- https://archives.lib.purdue.edu/repositories/2/resources/32
- Sottile, R. J., & Vida, T. (2022). A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. Frontiers in psychiatry, 13, 991753.https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.991753/full
- Bedi, G., Phan, K. L., Angstadt, M., & De Wit, H. (2009). Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology, 207(1), 73-83.https://pmc.ncbi.nlm.nih.gov/articles/PMC3328967/
- Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016). Clinical applications of hallucinogens: A review. Experimental and clinical psychopharmacology, 24(4), 229.https://www.researchgate.net/publication/305644612_Clinical_applications_of_hallucinogens_A_review
- Betzler, F., Viohl, L., & Romanczuk‐Seiferth, N. (2017). Decision‐making in chronic ecstasy users: a systematic review. European journal of neuroscience, 45(1), 34-44.https://onlinelibrary.wiley.com/doi/10.1111/ejn.13480
- Montgomery, C., & Roberts, C. A. (2022). Neurological and cognitive alterations induced by MDMA in humans. Experimental Neurology, 347, 113888.https://www.sciencedirect.com/science/article/abs/pii/S001448862100296X
- Bedi, G., Phan, K. L., Angstadt, M., & De Wit, H. (2009). Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology, 207(1), 73-83.https://pmc.ncbi.nlm.nih.gov/articles/PMC3328967/
- Frye, C. G., Wardle, M. C., Norman, G. J., & de Wit, H. (2014). MDMA decreases the effects of simulated social rejection. Pharmacology Biochemistry and Behavior, 117, 1-6.https://pubmed.ncbi.nlm.nih.gov/24316346/
- Bershad, A. K., Mayo, L. M., Van Hedger, K., McGlone, F., Walker, S. C., & de Wit, H. (2019). Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharmacology, 44(10), 1698-1705.https://pmc.ncbi.nlm.nih.gov/articles/PMC6785008/
- de Wit, H., Bershad, A. K., Hutchison, W., & Bremmer, M. (2021). Can MDMA change sociopolitical values? Insights from a research participant. Biological Psychiatry, 89(11), e61-e62. https://pubmed.ncbi.nlm.nih.gov/33814127/



Leave a comment